INHIBITOR Therapeutics Inc a biopharmaceutical company focused on the discovery development and commercialization of innovative therapeutics to inhibit progression of cancerous and noncancerous proliferation disorders today announced that the company has received Investigational New Drug IND clearan...

Genialis a leader in applied data science for the development of precision medicines today announced a collaborative partnership with Oncologie an international clinicalstage biopharma developing nextgeneration immunotherapies for cancer Initial activities will focus on the use of Genialis Expressio...

Hitachi Chemical Advanced Therapeutics Solutions LLC HCATS a US subsidiary of Hitachi Chemical Co Ltd that engages in contract manufacturing and manufacturing development of cell therapy products and Ori Biotech Ltd Ori an innovator in cell and gene therapy CGT manufacturing today announced they hav...

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell iPSCderived cardiomyocytes Under the terms of the agreement Bluerock gains access to Ncardias largescale production processes and intellectual...

Crescita Therapeutics Inc a commercial dermatology company with manufacturing capabilities and a portfolio of nonprescription skincare products and prescription drug products for the treatment and care of skin conditions diseases and their symptoms today announced that it has entered into a distribu...

Bridge Biotherapeutics Inc a clinical stage biotech company headquartered in Seongnam Republic of Korea announced that the Investigational New Drug IND application submitted to the US Food and Drug Administration FDA has been cleared on January th

Mundipharma today announced a partnership with Samsung Bioepis to commercialize the first biosimilar candidates from Samsung Bioepis in Taiwan and Hong KongThe partnership includes biosimilar candidates from Samsung Bioepis in the field of immunology and oncology including SB adalimumab SB etanercep...

Jazz Pharmaceuticals plc announced the submission of a New Drug Application NDA to the US Food and Drug Administration on January seeking marketing approval for JZP an investigational medicine for the treatment of cataplexy and excessive daytime sleepiness EDS in patients years of age and older...

Aruvant a clinicalstage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders today announced that the US Food and Drug Administration has granted Orphan Drug designation to ARU Aruvants investigational therapy for th...

Denovo Biopharma LLC a pioneer in applying precision medicine to develop innovative therapies today announced it has entered into an exclusive OptiontoLicense Agreement with Rumpus Therapeutics for selected indications for DB Rumpus Therapeutics gains the option to acquire an exclusive license to de...

OBI Pharma Inc a Taiwan biopharma company TPEx today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation for OBI for the treatment of Gastric Cancer OBI is a firstinclass antibody drug conjugate targeting Globo H a glycolipid antigen On December OBI was gran...

As the pharmaceutical market demands in China continue to grow Chinas pharmaceutical policies become gradually clear which provides broad space for the development of pharmaceutical enterprises The CRO CMO industry an important part of the RD industry chain of pharmaceutical enterprises has also us...

FDF Chinacollocated with CPhI China will be held fromJune at Shanghai New International Expo Centre SNIEC More and more formulation enterprises need to implement strategic layout to step up cooperation in innovation and facilitate the integration of science and technology with economic growth and...